TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oxidative Stress on Muscle Dysfunction in Hemodialysis Patient

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 40-80 years old~* less than 150min by week of moderate to vigorous physical activity~* Chronic renal failure (glomerular filtration rate less than 15mL by min) requiring hemodialysis~* Patient placed on the kidney transplant waiting list of MontpellierCHU~* No indication against temporary kidney transplant~* Review cardiovascular older than two years~* Patient not under guardianship or trusteeship~* Clinically stable state Absence or recent infection within 3 months prior to inclusion Absence of progressive neoplasia No recent acute decompensation of chronic disease (thrust of heart failure, respiratory decompensated cirrhosis).~Absence of recent stroke~* musculoskeletal and neurological states of the lower limbs which allow the realization of the proposed functional tests.~* Patient has given written informed consent~* Absence of congenital or genetic degenerative muscle disease~Exclusion Criteria:~* Terminal chronic renal failure without replacement therapy~* Local anesthesic hypersensibility~* Corticosteroid treatment upper than 3 month~* COPD~* Oral anticoagulants~* Previous renal transplantation~* Subject not affiliated with a social security scheme, beneficiary or not such a plan~* Major subject protected by law or unable to consent under Article L 1121-8 of the Public Health Code~* Vulnerable person under Article L.1121-6 of the Public Health Code

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- HD patient (Type: EXPERIMENTAL): None
- Healthy volunteers (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Signed study-specific consent form prior to registration.~* Pathologically confirmed malignant melanoma.~* Measurable melanoma lesion deemed to require radiation by treating physicians for purposes of local control or palliation. The lesion may be the primary melanoma, a nodal metastasis, or a distant metastasis. Recurrent lesions are allowed.~* Lesion has to be measurable clinically or radiographically in 2 dimensions.~* Karnofsky Performance Scale (KPS) \> 70.~* Laboratory values~  * White blood cells (WBC) \> 3000/mm3~ * Absolute granulocyte count \> 1,500~ * Platelets \> 100,000/mm3~ * Total bilirubin \< 2.0 x institutional upper limit of normal~ * AST or ALT (aminotransferase/alanine aminotransferase) \< 2.5 x institutional upper limit of normal~ * Serum calcium \< 1.3 x institutional upper limit of normal~ * Serum creatinine \< 1.5 mg/dL or Creatinine clearance \> 50 cc/min,calculated as follows: CCr = 0.85 x (140-age) x (weight in kg) 72 x serum creatinine in mg/dL~Exclusion criteria:~* Systemic therapy for malignant melanoma within one month preceding trial enrollment.~* Prior irradiation to the planned field.~* Concomitant chemotherapy (in addition to cisplatin) or biologic therapy is allowed.~* Significant infection or other co-existent medical condition which would prevent the use of full dose chemotherapy.~* Pre-existing sensory neuropathy (CTC 3.0 ≥ Grade II)~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anticholinergic Burden in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 50 and older~* DSM-IV/SCID diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder NOS~* Having been treated with benztopine at a steady daily dose of 3 mg or less for at least three months~* Having been treated with risperidone, quetiapine, olanzapine, or clozapine at a steady dose for at least two weeks.~* Willingness to provide consent for investigator to communicate with their physician of record regarding their participation in the study.~Exclusion Criteria:~* Unstable physical illness or clinically significant neurological disorder~* A history of severe or life-threatening dystonia~* Presence of EPS defined as a total score of 7 or more or a score of 3 or more on any individual item on the SAS at baseline~* Positive urine drug screen for illegal drugs

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years old.~* Histologic proof of melanoma reviewed and confirmed by MSKCC.~* A confirmed EBRAFV600E or KBRAFV600K mutation.~* Stage IV melanoma, or advanced stage III not curable by surgery. Patients with active CNS metastases will be allowed on the study.~* Measurable disease by RECIST v1.1.~* ECOG performance status 3 or 4. The basis for the grading of performance is strict; there must be clear justification of the performance status grade (e.g. patient is confined to bed \> 50% of time, or cannot carry out ADLs, or is otherwise disabled by burden of disease such as requiring supplemental O2).~* Patients must be able to swallow pills~* Adequate hematologic, hepatic and renal function as defined by the following:~* Absolute Neutrophil Count ≥ 1.0 x 109/L~* Hemoglobin ≥8.0g/dL, occasional transfusions are acceptable as vemurafenib does not have significant hematologic toxicities.~* Total bilirubin ≤2.0x the upper limit of normal, ≤3.0x the upper limit of normal if the patient has Gilbert's Syndrome.~* Alkaline phosphatase ≤2.0x the upper limit of normal.~* AST and ALT ≤2.0x the upper limit of normal.~* Serum creatinine ≤ 1.5x the upper limit of normal.~Exclusion Criteria:~* Uveal melanoma as primary.~* Concurrent chemotherapy, immunotherapy, or radiotherapy.~* Prior treatment with a RAF inhibitor. Other prior chemotherapy, immunotherapy, or radiotherapy will be allowed including prior treatment with a MEK inhibitor Patients must have had complete recovery from any adverse events or toxicities of prior cancer-directed therapies.~* Pregnant or lactating women.~* A second active malignancy. Prior malignancy will be allowed as long as the patient is known to be free of disease for at least 2 years. Patients with indolent B-cell malignancies will not be eligible.~* QTc interval \> 500 msec.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vemurafenib (Type: EXPERIMENTAL): This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EFFECTIVENESS: Hopewell Hospitalist: A Video Game Intervention to Increase Advance Care Planning by Hospitalists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Hospitalist Inclusion Criteria:~* Employed by Sound~* Not previously included in the Efficacy Trial Arm of the study.~Hospitalist Exclusion Criteria:~* Not employed by Sound~* Does not provide informed consent~* Previously included in the Efficacy Trial Arm of the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control: Usual Care (Type: NO_INTERVENTION): The control arm occurs prior to receipt of the video game intervention and reflects usual care. Each hospitalist 'crosses over' from control to intervention at a single time point.
- Video Game Intervention (Type: EXPERIMENTAL): Each hospitalist 'crosses over' from control to intervention at a single time point by receiving a link to the Hopewell Hospitalist game via email and logging in to play the video game.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females - 18 years or older~* Been convicted of drinking driving and allocated to either the education or the treatment group of the BOT program~* Meet criteria for alcohol dependence using the SCID-IV~* Consume more than 14 drinks (female) or 21 drinks (male) per week with a minimum of 2 heavy drinking days (≥ 4 drinks for females and ≥ 5 drinks for males) during a consecutive 30-day period within the 90 days prior to the baseline evaluation~* Willing to receive pharmacotherapy for their alcohol dependence~* Seeking abstinence from alcohol as their main goal~Exclusion Criteria:~* History of other substance use (other than nicotine or cannabis) by DSM-IV criteria in the last 90 days (6 months for opiate abuse)~* Positive urine drug screen~* Psychiatric disorder requiring medication~* Unstable medical condition requiring immediate investigation or treatment~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
- Control (Type: PLACEBO_COMPARATOR): Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBsAg positive for more than 6 months~* HBeAg positive~* ALT≥80U/L or inflammation score ≥2 of histological examination~Exclusion Criteria:~* History of drug allergy to GM-CSF~* coinfection with HCV, HIV, HAV, HEV~* liver cirrhosis or CHILD score \>7~* diagnosis of hepatocellular carcinoma or AFP\>100ng/ml~* Allergic thrombocytopenic purpura

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ETV+GM-CSF (Type: EXPERIMENTAL): Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
- ETV monotherapy (Type: ACTIVE_COMPARATOR): As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients (\>18 years old)~2. In the ICU \> 48 hours~3. Mechanically ventilated (\>48 hours)~4. Grow a Candida spp. on respiratory tract secretion culture (either by Bronchoalveolar Lavage or Endotracheal Aspirate) taken on or between 48 hours before or after the day of their suspicion of respiratory tract infection.~5. Develop a clinical suspicion of respiratory tract infection while ventilated as defined by the following criteria (as defined previously in our VAP trial)5:~   * The presence of new, worsening or persistent radiographic features suggestive of pneumonia without another obvious cause AND~  * The presence of any two of the following:~     * Fever \> 38C (core temperature)~    * Leukocytosis (\>11.0 x109/L) or neutropenia (\<3.5 x109/L)~    * Purulent endotracheal aspirates or change in character of aspirates~    * Isolation of pathogenic bacteria from endotracheal aspirates~    * Increasing oxygen requirements~Exclusion Criteria:~1. Patients not expected to be in ICU for more than 72 hours (due to imminent death, withdrawal of aggressive care or discharge).~2. Patients with Candida spp. in the blood or another sterile body site.~3. Patients colonized at other non-pulmonary body site(s) with Candida.~4. Already being treated with antifungal drugs (because of documented fungal infection, pre-emptive therapy, or prophylaxis).~5. Allergy to study drugs (Fluconazole or the Echinocandin on formulary at treating institution).~6. Immunocompromised patients (post-organ transplantation, Acquired Immunodeficiency Syndrome \[AIDS\], neutropenia \[\<1000 absolute neutrophils\], corticosteroids \[\>20 mgs/day of prednisone or equivalent for more than 6 months\]). These patients are excluded since Candida may be more invasive and these patients are much more likely to require systemic antifungal therapy.~7. Patients with fulminant liver failure or end stage liver disease (Child's Class C).~8. Women who are pregnant or lactating.~9. Enrollment in industry sponsored interventional trial (co-enrollment in other academic studies would be allowed with the proviso that there was no potential interaction between the protocols).~10. Prior randomization in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Saline will serve as the placebo solution since the active comparator is clear and colourless.
- Antifungal (Type: ACTIVE_COMPARATOR): Patient will receive a dose daily for a total of 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.~* Patients must have high-risk neuroblastoma according to COG risk classification at the time of study enrollment.~* Patients must have at least ONE of the following: 1) Recurrent/progressive disease at any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease~* Patients must have at least ONE of the following: 1) Bone disease, 2) Any amount of neuroblastoma tumor cells in the bone marrow, 3) At least one soft tissue lesion that meets criteria for a TARGET lesion.~* Patients must have a Lansky (\< 16 years) or Karnofsky (\> 16 years) score of at least 50~* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.~* Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.~* Patients must not be receiving other investigational medications (covered under another IND) within 30 days of study entry or while on study.~* Patients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).~* Patient must meet the organ function requirements as stated in the protocol.~Exclusion Criteria:~* Pregnancy, breast feeding, or unwillingness to use effective contraception during the study.~* Patients status post-allogeneic stem cell transplant are not eligible.~* Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.~* Patients with disease of any major organ system that would compromise their ability to withstand therapy.~* Patients who are on hemodialysis.~* Patients with an active or uncontrolled infection.~* Patients with known intraparenchymal brain metastasis at study entry are excluded due to poor CNS penetration of SF1126.~* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.~* Patient declines participation in NANT 2004-05, the NANT Biology Study.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- SF1126 (Type: OTHER): Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female children,~* ages 4-8 years,~* diagnosed with an ASD, including~* Pervasive Developmental Disorder NOS (PDD, NOS),~* Asperger's Syndrome, or~* Autistic Disorder, and followed in the Munroe Meyer Developmental Pediatrics Clinic. Documented impaired sleep maintenance (ISM) based on parent-report and 7 day somnolog (sleep diary).~* Clinician rating of 4 (moderately ill) or worse on CGI-S. Rating is based on the clinician's experience with evaluating and treating this patient population.~* Previous discussion during a clinic appointment about sleep difficulties, including review of sleep hygiene and basic behavioral interventions/strategies.~* Current problems of overnight awakenings recorded on the Children's Sleep Habits Questionnaire (CSHQ) despite behavioral intervention.~* Stable psychotropic medication treatment for the past 4 weeks.~Exclusion Criteria:~Treatment with Melatonin or Melatonin CR during the past month or previous failed treatment with Melatonin CR.~Presence of a previously unevaluated medical condition which may be the etiology of the nighttime awakenings. There is no contraindication for use of Melatonin CR in patients with obstructive sleep apnea.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- Natrol (Type: EXPERIMENTAL): Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multi-cap for Increase Adherence After Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years old~* Myocardial infarction within seven (7) days prior: anginal symptoms with ST-segment changes (elevation or depression) or inversion of T waves or left bundle branch block and acute elevation of cardiac enzymes.~* Signature of written informed consent~Exclusion Criteria:~* Severe ventricular dysfunction, (ejection fraction of the left ventricle less than 40%)~* Contraindication for beta-blockers, angiotensin-converting enzyme, aspirin and / or statins.~* History of allergies or adverse reactions to some of the study drug reactions. Chronic treatment with NSAIDs. Planned coronary-revascularization within six months after discharge.~* Renal failure with estimated creatinine clearance according to the Cockroft-Gault formula less than 30 ml / min.~* Liver or elevated transaminases before randomization more than three times the upper normal limit.~* Higher fasting triglycerides 500 mg / dl.~* Indication according to medical criteria other than a beta-blocker atenolol.~* Indication of oral anticoagulation.~* Failure to follow due to difficulties of geographical access.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Combined capsule (Type: EXPERIMENTAL): Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
- Conventional treatment (Type: OTHER): Usual therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy